SCHEMBL6758172

SCHEMBL6758172

Cc1ncc(-c2cccc(NC(=O)/C=C/c3ccc(Cl)cc3)c2)n1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.56
DYRK1A Q13627 2/20 0.56
MEN1 O00255 2/20 0.54
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.54
TRPV1 Q8NER1 2/20 0.54
NPC1 O15118 2/20 0.54
MAPK1 P28482 2/20 0.54
HDAC6 Q9UBN7 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TP53 P04637 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
TSHR P16473 1/20 0.54
CYP2C19 P33261 1/20 0.54
MMP1 P03956 7/20 0.50
MMP2 P08253 7/20 0.50
MMP9 P14780 7/20 0.50
MAOB P27338 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6758174 1.00 GSK3B (0.56) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6754336 0.91 GSK3B (0.55) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6754332 0.91 GSK3B (0.55) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6756808 0.91 GSK3B (0.65) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6756807 0.91 GSK3B (0.65) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6754391 0.87 MAOB (0.58) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6754387 0.87 MAOB (0.58) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6755701 0.87 MAPT (0.52) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6755704 0.87 MAPT (0.52) GSK3BDYRK1AMEN1MAPTKMT2A
SCHEMBL6759913 0.86 DYRK1A (0.54) GSK3BDYRK1AMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 GSK3B 4671/4885DYRK1A 3409/4885MEN1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.